Metropolis Healthcare Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Core revenue grew 15% YoY, margin held: Q4 core revenue growth of 15% was driven by 7% volume and 13% RPP, while reported EBITDA margin of 25.5% is deemed sustainable into FY25.
• B2C leads with 20% growth, price hike absorbed: A January price increase lifted B2C revenue 20% YoY without sacrificing volumes, which stayed at 7%+ growth, signaling strong brand pull.
• Competitive intensity is easing: Discounts are stable to marginally down, new entrants are struggling to scale profitably, and unorganized players continue losing share to organized incumbents.
• Dividend cut signals M&A appetite: Payout ratio drops from 30-35% to 15-20% of PAT for the next couple of years to conserve cash for acquisitions, with a promise to restore it once growth initiatives are executed.
• What to watch next quarter: Whether the 13-15% FY25 revenue growth guidance holds, the pace of M&A deployment given the pipeline of opportunities, and the margin impact of adding another 25 labs this year.

Competitive Landscape

• New entrants hitting a wall: Players attracted by high margins during 2020-2022 found scaling profitable revenue difficult; aggressive pricing worked in wellness but not in illness, where trust and institutional knowledge matter more.
• HealthTech conversion failure: HealthTech firms hoped to acquire via wellness and convert to illness, but conversion rates remain low single digits; global examples like Theranos and 23andMe are struggling in pure wellness, and there is no structural cost advantage in their model, just cash burn to acquire customers.
• Hospital entrants face structural limits: Hospitals charge 50-100% higher prices for pathology inside their walls, creating customer dissonance when they try to price competitively outside; specialized doctors outside hospitals also fear patient leakage if they refer to a hospital lab.
• Unorganized sector losing ground: The emergence of organized players has shifted customer attitudes, causing unorganized standalone labs to lose market share; the organized segment is growing faster than the ~10% industry CAGR.
• Discount stability confirms easing: Discounts did not change much YoY and showed a slight decrease, meaning competitive intensity has stabilized and is marginally coming down.

Ameera Shah: "while entering the market is easy, scaling up profitable revenue poses a significant challenge for new entrants. And while aggressive pricing can play a role in creating the wellness market, it has not proven to be a silver bullet in the illness thing."

Revenue Growth & Channel Mix

• B2C outperformance: B2C revenue grew 20% YoY, driven by 7% volume growth and 13% RPP increase from the January price hike and product mix shift; the price increase was effectively absorbed with volumes maintained.
• B2B recovery underway: B2B revenues grew 11% with 7% volume growth; discounting in B2B reduced compared to full year FY23, and dedicated relationship managers, a centralized help desk, and a partner portal have helped rationalize discounts while lifting volumes.
• Mumbai as a growth engine: Revenue from Mumbai grew 20%, underscoring increased market share and brand pull in core geographies; the company plans to expand Mumbai centers from 430 to 500-plus in the coming year, targeting one collection center every 2.5-3 kilometers.
• Tier 2 and 3 cities accelerating: Revenue from other cities grew 34% in Q4 and 28% for the full year, largely on the back of tier 2 and tier 3 markets; new labs added over the last 12 months contributed 4% of full-year revenue and are showing robust growth.
• Specialized and wellness testing: Specialized testing grew 17% YoY, wellness grew 22% YoY; wellness growth is strongest in the top 4-5 cities, with the next set of cities picking up on a smaller base but at better growth rates.
• Volume softness post price hike: In non-core markets, there was slight volume softness immediately after price increases, then stabilization and return to normalcy; some corrections were made in markets where the impact was relatively higher.

Margins & Profitability

• Q4 margin composition: Reported EBITDA margin was 25.5%; prior to CSR and ESOP it was 26.5%; adding back new lab dilution cost it was 27.4%. One-off expenses of ₹6.8 crore were booked on account of a whistleblower and Aam Aadmi Mohalla Clinic provision.
• Segment profitability dynamics: Gross margins on routine tests tend to be higher, while gross margins on specialized tend to be lower; however, specialty as a segment gives better net profitability with a stronger competitive moat, and B2C as a channel gives better profitability than B2B.
• Price increase by segment: Price increases were done across the spectrum, with higher increases for routine tests because B2C comes through that channel, and lesser increases on semi-specialized tests because that area comes more from B2B, which is more price-sensitive.
• Lab addition dilution: The next 25 labs will carry a dilution of a bit under one percentage point; the guided 25.5% to 26% margin already considers that dilution.

Ameera Shah: "See, I think we are comfortable with our Q4 margin. We believe that we will be able to sustain that into the next year and hopefully try to expand it as the volumes grow and we are able to execute some synergy. So, I think 25.5% to 26% margin, give or take, I think, is sustainable."

M&A Strategy & Capital Allocation

• Dividend policy reset: The company plans to alter dividend payout from the historic 30-35% of PAT to 15-20% of PAT for the next couple of years to retain cash for M&A; once growth initiatives are successfully executed, the payout will be restored to historical levels, if not higher.
• Three-lens M&A framework: Acquisitions will target (1) firms with cutting-edge technical testing capabilities to sell through Metropolis's distribution network, (2) ethical, strong local B2C players in markets without a strong consumer presence, largely in the North and East but also specific cities in the South and West, and (3) subscale brick-and-mortar firms making losses that can be turned around using management skills, advanced testing, and brand recognition.
• Valuation environment improving: Valuation expectations have modulated compared to the COVID period; management currently sees a fair number of opportunities to buy assets that meet both strategic and financial checklists.
• Funding approach: Deals will be funded using internal cash accruals, external debt, and own stock; each deal will be assessed from an IRR, ROCE, and ROE perspective, with financial conservatism in allocating capital or raising debt.
• Balance sheet strength: The company achieved zero debt in the last quarter, with a net cash surplus of ₹117 crore as of 31st March 2024; working capital days reduced from 14 to 7, and operating free cash flow to EBITDA stood at 105%.

Network Expansion & Operations

• Lab expansion plan: 24 new labs were added in the last 12 months, 7 in the last quarter; the plan for the current financial year entails adding another 25 labs in strategic locations to target underserved markets, aiming for accelerated revenue growth and market share expansion.
• Post-FY25 expansion: Beyond FY25, the company expects to add about six, seven, or eight labs, well under 10, to specific markets for further penetration.
• International B2B opportunity: The company plans to expand B2B presence to new markets outside India using its global reference lab in Mumbai as a specialty hub, in an asset-light model that moves samples from outside India to Mumbai.
• Digital channel growth: Revenue contribution led by digital channels showed robust growth in the full year FY24.
• Test volume reporting change: Management plans to change how test volumes are presented in FY25, recalibrating numbers to give real test volume including a breakup within wellness packages; currently, a wellness profile with 10 tests inside is declared as one test.

Leadership & Governance

• Leadership transition: Ameera Shah is transitioning to Executive Chairperson and Whole-Time Director; Dr. Sushil Shah is transitioning to Chairman Emeritus and Director on the board; Surendran Chemmenkotil as CEO will lead execution of operational initiatives, reporting to Ameera Shah.
• Governance philosophy: The move is designed to delineate and separate governance from operations, running the firm as a promoter-led but professionally managed company.
• Organization strengthening: The organization structure has been simplified, and senior professionals from diverse industries have been brought in to strengthen the leadership bench.

Ameera Shah: "we believe it is the opportune moment to delineate and separate governance from operations and run the firm as a promoter-led but professionally managed Company."

Guidance & Commitments

Key Metrics